EBITDA

Groundbreaking lymphoma data and a strategic acquisition position Natera to dominate the liquid biopsy market, challenging old standards and creating new value.

TransAlta is converting a massive coal plant to natural gas, a pragmatic yet controversial move in the push for a cleaner, reliable energy future.

Beyond the award, Pariveda's use of generative AI to modernize legacy systems reveals a powerful new playbook for enterprise transformation and value.

With its new 'Eagle Line' pilot facility online, QuantumScape takes a leap toward the EV future. We analyze the tech, the risks, and the competition.

A key safety milestone for Opus Genetics' OPGx-BEST1 gene therapy trial offers a glimmer of hope for thousands facing progressive vision loss from Best disease.

With validated Phase 1b data, ONL Therapeutics' novel drug aims to protect vision cells, not just slow disease, in a challenge to current GA therapies.

A landmark private equity deal in Europe's produce sector is about more than money; it's a strategic move to build a resilient food supply chain.

Beyond the press release: How two strategic hires signal Plus Therapeutics' aggressive push to commercialize its CNSide platform and capture a $6B market.

A new lab system combines speed, multiplexing, and regulatory trust, promising to accelerate drug development and deepen our biological understanding.

With a critical $1.74M lifeline, Northstar Clean Technologies is racing to prove its shingle recycling tech can be a profitable circular economy champion.

A $900k stock grant to a new exec reveals more than a salary. It's a look into biotech's talent war and the financial tools used to secure human assets.

A new initiative empowers local leaders to deploy a data-backed 'catch-up' learning method, aiming to solve Africa's foundational education crisis.

With stellar clinical data for its TERN-701 drug, Terns is raising massive capital to challenge Novartis and reshape the multi-billion-dollar CML market.

A deep dive into the valuation impasse that scuttled a major oil merger, and what the fallout means for Parex, GeoPark, and Latin American energy M&A.

For those with severe PTSD and depression, hope is scarce. Biotech firm Compass Pathways is pioneering a psilocybin treatment that could change everything.

The platform's 2025 report reveals more than just charity; it's a real-time indicator of economic distress, disaster response, and tech-driven mutual aid.

A leading stainless steel giant partners with a spiritual organization to tackle addiction, signaling a strategic shift in corporate social responsibility.

New AI tech lets car dealers profile you on arrival. It promises efficiency, but at what cost to your privacy and power in the negotiation?

NUS scientists unveil a microneedle patch for plants, slashing waste and boosting growth. A new investment frontier in high-end, sustainable agriculture.

A routine regulatory filing reveals Sintana Energy's major M&A play. We decode the signals, the Challenger deal, and what it means for its oil future.